Sign in
CompletedPhase 4

Rebamipide Versus Diquafosol and Cyclosporine for Perioperative Dry Eye in Cataract Surgery

Key facts

Who runs it
Samsung Medical Center
Where
South Korea1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
56 people enrolled
Started
1 Aug 2025
Ended
1 May 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Rebamipide 2% ophthalmic solution
  • Diquafosol 3% ophthalmic solution
  • Cyclosporine 0.05% ophthalmic solution
Record updated
27 October 2026

Who can take part

Age
40 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Adults scheduled for cataract surgery
  • Presence of dry eye disease, defined as an Ocular Surface Disease Index (OSDI) score ≥12 and at least one of the following:; Tear film breakup time (TBUT) ≤7 seconds; Oxford corneal staining grade ≥1; Schirmer's test value ≤10 mm/5 min
  • Ability and willingness to comply with the study protocol and follow-up schedule
  • Provision of written informed consent

Who cannot take part

  • Use of topical intraocular pressure-lowering medications
  • Presence of ocular surface or ocular conditions that could affect dry eye status (e.g., active keratitis or ocular infection)
  • History of ocular surgery other than cataract surgery in the study eye
  • Any systemic or ocular condition judged by the investigator to interfere with study participation or outcome assessment

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to compare the efficacy of 2% rebamipide monotherapy versus a combination therapy of 3% diquafosol and 0.05% cyclosporine for the management of dry eye disease in patients undergoing cataract surgery. It will also evaluate the safety and ocular surface stability effects of these treatments during the perioperative period.

Read full original descriptionShow less

The main questions it aims to answer are:

Does rebamipide monotherapy maintain tear film breakup time (TBUT) and prevent corneal damage as effectively as the combination therapy after surgery? How do patient symptoms (OSDI scores) and inflammation markers (MMP-9) change with each treatment?

Researchers will compare the rebamipide group to the diquafosol-cyclosporine combination group to evaluate their effects on perioperative dry eye management.

Participants will:

Use the assigned study eye drops starting 1 month before their cataract surgery and continuing for 3 months after surgery.

Visit the clinic for eye examinations at baseline, the day of surgery, and at 1 week, 1 month, and 3 months postoperatively.

Undergo tests including tear film breakup time measurement, corneal staining, Schirmer's test, and tear MMP-9 level assessments.

The 2 groups in the trial

  • Group RTreatment being tested

    Participants receive topical rebamipide 2% ophthalmic solution four times daily, initiated 1 month before cataract surgery and continued for 3 months postoperatively.

    Treatment: Rebamipide 2% ophthalmic solution

  • Group DCExisting treatment, for comparison

    Participants receive topical diquafosol 3% ophthalmic solution four times daily in combination with cyclosporine 0.05% ophthalmic solution twice daily, initiated 1 month before cataract surgery and continued for 3 months postoperatively.

    Treatment: Diquafosol 3% ophthalmic solution and Cyclosporine 0.05% ophthalmic solution

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Rebamipide Versus Diquafosol-Cyclosporine for Perioperative Dry Eye Disease in Cataract Surgery: A Randomized Trial
Record updated
27 October 2026